 "Marksans Pharma up 10% after falling 40% in one week")
Shares of Marksans Pharma were locked in 10% upper circuit at Rs 63 on the BSE after falling 40% in the past one week.
The pharmaceuticals firm today said it has responded to UK Medicines and Healthcare products Regulatory Agency (MHRA) observations on 16th December 2015.
In past five trading sessions, the stock tanked 40% from Rs 95 to Rs 57 till yesterday after the media report suggests that the company’s Goa plant get notification of deficiency in goods manufacturing practices (GMP) from UK MHRA.
“UK MHRA GMP inspection of the company’s Goa plant commenced on November 23 and ended on November 25. UK MHRA issued observation on December 2, 2015 and company acknowledged on the same date”, Marksans Pharma said on clarification on the report.
Till 03:02 p.m. a combined 11.9 million shares changed hands and there were pending buy orders 331,802 shares on the BSE and NSE.
The pharmaceuticals firm today said it has responded to UK Medicines and Healthcare products Regulatory Agency (MHRA) observations on 16th December 2015.
In past five trading sessions, the stock tanked 40% from Rs 95 to Rs 57 till yesterday after the media report suggests that the company’s Goa plant get notification of deficiency in goods manufacturing practices (GMP) from UK MHRA.
“UK MHRA GMP inspection of the company’s Goa plant commenced on November 23 and ended on November 25. UK MHRA issued observation on December 2, 2015 and company acknowledged on the same date”, Marksans Pharma said on clarification on the report.
Till 03:02 p.m. a combined 11.9 million shares changed hands and there were pending buy orders 331,802 shares on the BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%